Notably, CD69 expression, an activation marker for CD8+ T lymphocytes, significantly increased in the combination treatment group in contrast to the PBS group, PLX3397 group, and RT group within the Lewis subcutaneous transplant tumor model (Fig. 2F). The gene discussed is CD8A; the disease is neoplasm.